Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 12/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | PER2 | O15055 | 1/20 | 0.56 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.56 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858681 | 0.82 | DNM1 (0.67) | DNM1KDM4EALDH1A1BACE1PRMT1 | |
| SCHEMBL17138489 | 0.81 | DNM1 (0.65) | DNM1BACE1PRMT1 | |
| SCHEMBL28590219 | 0.79 | DNM1 (0.62) | DNM1BACE1PRMT1PER2CRY1 | |
| SCHEMBL410770 | 0.78 | DNM1 (1.00) | DNM1 | |
| SCHEMBL17138550 | 0.77 | DNM1 (0.60) | DNM1KDM4EALDH1A1BACE1PER2 | |
| SCHEMBL17138537 | 0.77 | DNM1 (0.60) | DNM1KDM4EALDH1A1BACE1PER2 | |
| SCHEMBL17138535 | 0.77 | DNM1 (0.60) | DNM1KDM4EALDH1A1BACE1PER2 | |
| SCHEMBL408965 | 0.75 | DNM1 (1.00) | DNM1KDM4EALDH1A1BACE1PER2 | |
| SCHEMBL14889275 | 0.75 | BACE1 (1.00) | DNM1BACE1PER2 | |
| SCHEMBL28545938 | 0.74 | DNM1 (0.63) | DNM1BACE1PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175805-A1 | Neuraminidase Inhibitors and uses thereof | ENGASE, NEU1, NEU2 | DNM1 1571/4885KDM4E 2155/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.